Brand Name Manufacturers

Lupron by Tap

Generic Manufacturers

None company

Pharmacology

GnRH agonist. After an initial stimulating phase, the pituitary is desensitized to GnRH, which causes it to stop producing LH, which in turn dramatically decreases gonadal production of hormones within one month.

Delivery

5, 7.5, 11.25, 15, 22.5mg sustained-release intramuscular injection

Typical dosage

Pre-op 3.75-7.5mg/month

Availability

Approved by U.S. FDA

Indications

Advanced prostate cancer. Endometriosis.

Contraindications

Hypersensitivity to GnRH or GnRH analogs.

Adverse reactions

CNS

Anxiety. Delusions. Dizziness. Headache. Hearing disorders. Insomnia. Memory disorder. Nerve disorders. Personality disorder.

Eyes

Eye disorders.

Gastrointestinal

Anorexia. Constipation. Coughing up blood. Dry mouth. Nausea. Thirst. Vomiting.

Skin

Change of facial and body hair. Skin rash.

Other

Ankylosing spondylosis. Blood in the urine. Bone and muscle pain. Change in heart electrical activity. Congestive heart failure. Decrease of bone density. Decreased tolerance of protein. Decreased red blood cell count. Decreased white blood cell count. Difficulty urinating. Elevated blood pressure. Elevated LDH. Elevated phosphorus. Escape of blood into the tissues from ruptured blood vessels. Fluid retention. Hair loss. Hot flashes. Increased heart beat rate. Increased uric acid. Increased urination frequency or urgency. Lactation. Liver disorder. Loss of strength. Low blood pressure. Lymphadenopathy. Mild to extreme allergic reaction. Palpitations. Pelvic fibrosis. Penile swelling. Prostate pain. Pulmonary disorders. Respiratory disorders. Temporary increase of hormone production. Temporary suspension of respiration and circulation.